Moderna on May 21 said it withdrew its application for a license for its combination vaccine against COVID-19 and influenza.
The move came “in consultation with” the Food and Drug Administration, which decides on licensing applications, the Massachusetts-based pharmaceutical company said in a brief statement.
The combination shot is known as mRNA-1083.
“The Company plans to resubmit the [application] later this year, after vaccine efficacy data from the ongoing Phase 3 trial of its investigational seasonal influenza vaccine, mRNA-1010, are available,” Moderna stated. “Moderna continues to expect interim data from the mRNA-1010 trial to be available this summer.”
Moderna and some other vaccine makers began testing combination COVID-19–flu shots during the COVID-19 pandemic. The company said in 2024 that its combination vaccine performed well in a phase 3 clinical trial. Moderna researchers said in May that in the trial, the vaccine elicited immune responses that were at least as good as those from standard influenza vaccines and its COVID-19 vaccine….